欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

休市中 10-09 16:08:08

5.080

+0.030

+0.59%

最高5.095	最低4.980	成交量40.65万
今开5.010	昨收5.050	日振幅2.28%
总市值41.40亿	流通市值41.40亿	总股本8.15亿
成交额203.66万	换手率0.05%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":5.08,"timestamp":1791533288001,"preClose":5.05,"halted":0,"volume":406500,"delay":0,"changeRate":0.00594059405940599,"floatShares":815000000,"shares":815000000,"eps":-0.2347138831987317,"marketStatus":"休市中","change":0.03,"latestTime":"10-09 16:08:08","open":5.01,"high":5.095,"low":4.98,"amount":2036587,"amplitude":0.022772,"askPrice":5.09,"askSize":9000,"bidPrice":5,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-0.18541692631050208,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":5.05,"openAndCloseTimeList":[[1791509400000,1791518400000],[1791522000000,1791532800000]],"volumeRatio":1.2677239657313089,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2674927897","title":"AI赋能，这个赛道走出独立行情！","url":"https://stock-news.laohu8.com/highlight/detail?id=2674927897","media":"格隆汇APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674927897?lang=zh_cn&edition=full","pubTime":"2026-10-10 18:00","pubTimestamp":1791626400,"startTime":"0","endTime":"0","summary":"最近的创新药板块里，AI制药这条细分赛道悄悄走出了独立行情。对比已上市的尼达尼布、吡非尼酮仅能延缓肺功能下降的临床现状，这款由AI设计的候选药物展现出潜在的差异化疗效优势。脱离了湿实验的AI制药，就是空中楼阁。但要注意区分，很多公司只是给传统业务套个AI概念，没有真实的BD订单和临床管线支撑，行情走不远。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwNjExNDkyOA==&mid=2649877824&idx=2&sn=0232fd9a16211b8c9949766afcb57a21&chksm=820d3809907314e1d353cbd99d49d2f7590c0f3d0c227a71aa792870b72151a116133803e954&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674863816","title":"国泰海通｜医药：AI制药9月跟踪报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2674863816","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674863816?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:53","pubTimestamp":1791543180,"startTime":"0","endTime":"0","summary":"报告导读：本报告总结了9月份大模型、药企、服务商在AI制药领域的进展。国内交易清单持续拉长：英硅智能年内披露的9项BD合作合约潜在总值约73亿美元，晶泰科技与DoveTree合作潜在里程碑最高58.9亿美元，德睿智药AI设计的口服GLP-1小分子达成最高17.5亿元人民币的商业化合作。报告来源以上内容节选自国泰海通证券已发布的证券研究报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650541947&idx=3&sn=4b6ddc41cdb11416ea61316521c57bce&chksm=89c11a451c01e898cddc798c64091d05c8d823bbb0fe887a6ef698ed79062100814632025e32&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["01477","AGIX","BK1564","02611","BK1515","BK1147","BK1191","BK0201","BK1574","09939","BK0184","BK0012","BK0028","CHAT","AIPO","BK0183","BK0188","ARTY","BK1161","QTOC","BK0276","159938","601211","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674288952","title":"汇宇制药（688553）10月8日主力资金净买入1423.28万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674288952","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674288952?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:26","pubTimestamp":1791505565,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，汇宇制药报收于11.55元，下跌10.12%，换手率5.62%，成交量28.51万手，成交额3.39亿元。近5日资金流向一览见下表：汇宇制药融资融券信息显示，融资方面，当日融资买入2473.67万元，融资偿还2340.99万元，融资净买入132.68万元。汇宇制药主营业务：从事肿瘤治疗领域创新药和优质仿制药的研发、生产和国内外销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0239","BK1191","688553","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673300348","title":"罗克韦尔自动化携手行业领军者发起数字化 CMC 联盟，加速制药研发领域的数字化转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2673300348","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673300348?lang=zh_cn&edition=full","pubTime":"2026-10-08 21:00","pubTimestamp":1791464400,"startTime":"0","endTime":"0","summary":"罗克韦尔自动化携手行业领军者发起数字化CMC 联盟，加速制药研发领域的数字化转型  制药企业面临着越来越大的压力，需要在满足复杂监管要求的同时，加快研发进程并控制不断上涨的成本。\"罗克韦尔自动化全球生命科学行业副总裁Matt Weaver 表示，\"该联盟体现了推动制药行业发展的合作导向模式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5066142_ZH66142_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5066142_ZH66142_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0472753341.HKD","LU2264538146.SGD","LU1988902786.USD","ROK","BK4585","BK4096","LU0154245673.USD","MVPS","LU0124676726.USD","LU0689626769.HKD","LU1894683348.USD","XSW","BK4588","THMZ","LU0390134368.USD","BK1574","BK1191","LU0154245756.USD","BK4580","LU0511384066.AUD","LU1894683264.USD","LU1064131342.USD","01477","LU0069063385.USD","LU0289961442.SGD","LU0057025933.USD","LU0289739343.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673749075","title":"毕得医药：AI制药的发展对公司业务既有机遇，也有挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2673749075","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673749075?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:21","pubTimestamp":1791454870,"startTime":"0","endTime":"0","summary":"证券之星消息，毕得医药(688073)10月08日在投资者关系平台上答复投资者关心的问题。投资者提问：ai制药的发展，对公司分子彻块业务是利大于弊还是弊大于利毕得医药回复：尊敬的投资者，您好！AI制药的发展对公司业务既有机遇，也有挑战。一方面，AI技术有望提升新药研发效率，带动药物分子砌块需求；另一方面，也对产品创新及研发响应能力提出更高要求。公司将持续丰富产品矩阵，积极适应行业技术发展趋势。AI制药对公司业务的实际影响尚存在不确定性，敬请注意投资风险。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800025346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0216","688073","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673020130","title":"破发股汇宇制药跌10% 上市即巅峰募24.7亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2673020130","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673020130?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:03","pubTimestamp":1791450185,"startTime":"0","endTime":"0","summary":"中国经济网北京10月8日讯 汇宇制药 今日收报11.55元，跌幅10.12%。目前该股处于破发状态。　　上市当日，汇宇制药盘中最高报42.59元，创上市以来股价最高点。　　汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。　　汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20261008/32390272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","601066","BK1191","BK1574","BK0276","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673027691","title":"AI制药疯狂烧钱，传统药企的底牌还剩几张？","url":"https://stock-news.laohu8.com/highlight/detail?id=2673027691","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673027691?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:41","pubTimestamp":1791448905,"startTime":"0","endTime":"0","summary":"截至 2023 年底，全球有 24 个由 AI 发现的药物分子完成了一期临床，其中 21 个成功通过，一期成功率在 80% 到 90% 之间，远远高于传统药物一期临床 40% 到 65% 的历史平均水平。这也是为什么现在大量 AI 制药公司拿着融资，管线还停留在临床前或一期阶段，商业价值远远没有兑现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1790677209234316345","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["AGIX","ARTY","01477","BK1574","AIPO","BK1191","QTOC","CHAT","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673896025","title":"港股异动 | 创新药概念股午后跌幅扩大 歌礼制药-B(01672.HK)跌超10% 信达生物(01801.HK)跌近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673896025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673896025?lang=zh_cn&edition=full","pubTime":"2026-10-08 14:01","pubTimestamp":1791439309,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01801","LU1969619763.USD","LU0455707207.USD","LU2097828474.EUR","LU1831875114.USD","LU2097828557.USD","LU0326950275.SGD","KURE","LU2097828631.EUR","LU2488822045.USD","LU2242644610.SGD","LU2328871848.SGD","LU0244354667.USD","LU1188198961.HKD","BK1583","LU0502904849.HKD","01672","BK1191","BK1161","01477","LU0607220059.USD","BK1574","LU2097828805.USD","HK0000165453.HKD","LU0149534421.HKD","06978","LU0463099449.HKD","BK1589","BK1515","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673014937","title":"股市必读：汇宇制药新发布《自愿披露公司产品获得境外上市许可的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014937","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673014937?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:00","pubTimestamp":1791392435,"startTime":"0","endTime":"0","summary":"公司公告汇总自愿披露公司产品获得境外上市许可的公告四川汇宇制药股份有限公司子公司Seacross Pharma Ltd.近期收到法国国家药品和健康产品安全管理局核准签发的注射用紫杉醇上市许可，规格为100mg，上市许可号NL56380。该产品适用于转移性乳腺癌、转移性胰腺癌及非小细胞肺癌的治疗。目前该产品已在英国、法国等15个国家获得上市许可，并在塞尔维亚提交注册申请。公司已开展上市销售前期准备，但短期内对经营业绩不构成重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673018883","title":"2026年诺贝尔化学奖揭晓：两位科学家破解生命手性之谜 成果深刻影响制药产业","url":"https://stock-news.laohu8.com/highlight/detail?id=2673018883","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673018883?lang=zh_cn&edition=full","pubTime":"2026-10-07 19:55","pubTimestamp":1791374146,"startTime":"0","endTime":"0","summary":"法国化学家Henri B. Kagan与日本化学家Kenso Soai因在不对称有机合成中发现非线性效应与自催化现象，共同摘得2026年诺贝尔化学奖。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20261007/20261007195420_55478.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20261007/20261007195420_55478.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673275018","title":"东航空姐下跪事件乘客为上市公司董事长？万年青制药回应：恶意捏造，欧先涛及公司其他员工从未乘坐该航班，已向公安机关报案","url":"https://stock-news.laohu8.com/highlight/detail?id=2673275018","media":"扬眼","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673275018?lang=zh_cn&edition=full","pubTime":"2026-10-07 19:25","pubTimestamp":1791372300,"startTime":"0","endTime":"0","summary":"经公司核实，该内容与事实严重不符，欧先涛先生及公司其他员工从未乘坐该航班，上述信息系无任何事实依据的恶意捏造，已构成对公司董事长个人名誉及公司商业信誉的侵害。9月30日，“东航空姐下跪道歉”登上热搜，引发热议。10月3日，东航再通报“空姐下跪求乘客谅解”：旅客欧某某相关行为涉嫌扰乱民用航空器内秩序，严重侵害公司员工人格尊严和履职权益，公司已报案。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-10-07/doc-iniumcpx8065318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0235","BK0188","01477","BK1191","000789","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178059234","title":"欧康维视生物-B更新2026年9月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178059234","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178059234?lang=zh_cn&edition=full","pubTime":"2026-10-06 21:21","pubTimestamp":1791292883,"startTime":"0","endTime":"0","summary":"欧康维视生物-B于2026年10月6日发布2026年9月股份变动月报表，报告期为截至2026年9月30日的一个月。截至2026年9月30日，已发行普通股为815,382,414股，库存股为20,949,500股，总已发行股本为836,331,914股，较上期无变化。2021年8月31日采纳的“2021年购股权计划”则由月初时的45,232,718份减少至44,968,449份，原因是当月有264,269份期权失效，但本月并未因此发行新股或转让库存股份。公司表示，截至2026年9月底，总体股本结构保持稳定，未发生显著变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673058257","title":"【热门行业】光遗传学获2026年诺奖：产业仍处早期，眼科赛道临床进度领先（附相关标的）","url":"https://stock-news.laohu8.com/highlight/detail?id=2673058257","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673058257?lang=zh_cn&edition=full","pubTime":"2026-10-06 18:22","pubTimestamp":1791282120,"startTime":"0","endTime":"0","summary":"诺奖落地的消息引发市场对光遗传学、脑科学相关赛道的关注。从行业发展阶段来看，光遗传学整体仍处于产业化早期，基础科研仍是核心需求，临床商业化尚未全面兑现。下游临床应用端，眼科赛道临床进度相对领先，但全行业目前尚无光遗传学产品完成全流程审批并获批上市，从临床试验到产品上市仍存在重大不确定性。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/YWU1MjY3ODMwOTg1Nzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YWU1MjY3ODMwOTg1Nzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993152","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU0359201612.USD","BK1161","LU0043850808.USD","LU0140636845.USD","LU1720050803.USD","LU0181495838.USD","LU0128522744.USD","09969","LU0516422440.USD","09926","01952","IE00B0JY6N72.USD","LU0211977185.USD","LU0634319403.HKD","09688","LU0979878070.USD","LU0417516902.SGD","BK1191","LU0029874905.USD","LU0516423091.SGD","LU0516423174.USD","HK0000306685.HKD","LU0051755006.USD","BK1588","IBBQ","LU0572944931.SGD","KURE","LU1688375341.USD","LU0708995583.HKD","BK1576","LU0823426308.USD","LU0348767384.USD","LU1961090484.USD","02228","LU1242518931.SGD","01477","HK0000320264.USD","LU0456846285.SGD","LU2476274308.USD","LU0359202008.SGD","LU0540923850.HKD","01548","LU0708995153.HKD","LU0052750758.USD","02269","LU0819121731.USD","BK1574","LU0456827905.SGD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673031677","title":"歌礼制药-B午后涨近11% 减重复方制剂ASC36_35FDC临床前数据公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2673031677","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673031677?lang=zh_cn&edition=full","pubTime":"2026-10-06 14:33","pubTimestamp":1791268380,"startTime":"0","endTime":"0","summary":"模拟交易客户端歌礼制药-B午后涨近11%。截至发稿，股价上涨10.80%，现报9.03港元，成交额1046.08万港元。歌礼制药宣布，其减重复方制剂ASC36_35FDC的关键临床前数据在第62届欧洲糖尿病研究协会年会上以简短口头讨论形式发布。公开资料显示，ASC36_35FDC是利用歌礼专有的基于结构的AI辅助药物发现和超长效药物开发平台 技术自主开发的复方疗法。近期，公司宣布在获得FDA批准的IND后，已启动ASC36口服片用于治疗肥胖症的美国I期研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-06/doc-iniuhiti5735024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1191","BK1574","01672","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673561031","title":"港股异动 | 歌礼制药-B(01672.HK)午后涨超10% 减重复方制剂ASC36_35FDC临床前数据公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2673561031","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673561031?lang=zh_cn&edition=full","pubTime":"2026-10-06 14:27","pubTimestamp":1791268020,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","01672","BK1191","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673734038","title":"创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673734038","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673734038?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:54","pubTimestamp":1791251688,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，歌礼制药-B 涨11.78%，再鼎医药涨6.55%，金斯瑞生物科技涨5.30%，晶泰控股涨4.40%，中国生物制药涨3.96%，三生制药涨3.41%，药明生物涨3.16%，康方生物涨3.11%，云顶新耀涨3.10%，四环医药涨2.82%。2026ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993103","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422366.SGD","LU0708995153.HKD","IBBQ","BK1515","LU0348766576.USD","02269","01530","MEDX","LU0348784397.USD","159992","LU0823426308.USD","BK4139","LU0052750758.USD","LU0029874061.USD","KURE","02228","SG9999002463.SGD","BK4588","HK0000306701.USD","LU0029874905.USD","LU0359201612.USD","BK1141","IE00BPRC5H50.USD","LU1242518931.SGD","06978","ZLAB","LU0320764243.SGD","LU0417516902.SGD","BK1574","LU0140636845.USD","LU0516423091.SGD","01177","LU2778985437.USD","09926","LNGR","01672","BK1191","LU2476274308.USD","BK1161","01477","LU0348827113.USD","LU0320764599.SGD","IE00BZ08YT58.USD","01952","00460","LU0211977185.USD","09688","01548","BK1521","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673023700","title":"万年青制药回应“东航事件涉事旅客为董事长”传闻：不实，董事长已报警，不会影响正常经营","url":"https://stock-news.laohu8.com/highlight/detail?id=2673023700","media":"BUG","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673023700?lang=zh_cn&edition=full","pubTime":"2026-10-05 21:33","pubTimestamp":1791207180,"startTime":"0","endTime":"0","summary":"10月5日晚间消息，近日，网传9月28日MU6741航班客舱冲突事件涉事旅客为广东万年青制药股份有限公司董事长欧先涛，引发网友热议。10月3日，东航发布后续处置通报称，认定涉事旅客相关行为涉嫌扰乱机上秩序，已向公安机关报案，并暂停对该旅客的承运服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/chanjing/gsnews/2026-10-05/doc-iniuevrx9449016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","000789","BK0188","BK0235","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702239","title":"盐野义制药20亿美元收购IntraBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702239","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673702239?lang=zh_cn&edition=full","pubTime":"2026-10-05 20:01","pubTimestamp":1791201660,"startTime":"0","endTime":"0","summary":"该药物已在美国与欧盟获批，用于治疗 C 型尼曼匹克病引发的神经系统病症。盐野义将从个人、信托机构以及企业法人等现有股东手中收购 IntraBio 股权。盐野义表示，本次收购预计在 1112 月之间完成交割。盐野义通过收购直接拿到成熟上市产品以及对方的罕见病技术积累，快速补齐自身罕见病业务板块。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-05/doc-iniuerix2666077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702542","title":"复刻“半导体时刻”：AI制药版的“瓶颈交易”正在成形，谁是下一个“卖铲人”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702542","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673702542?lang=zh_cn&edition=full","pubTime":"2026-10-05 19:51","pubTimestamp":1791201072,"startTime":"0","endTime":"0","summary":"投资人Freda Duan发文指出，AI制药正在形成类似半导体\"瓶颈交易\"的结构性机会。核心逻辑在于：AI让失败实验也变成有价值的训练数据，湿实验室正从\"造药\"转型为\"造数据\"，DNA合成、蛋白生产、CRO或成最先受益的\"卖铲人\"。","market":"other","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3783019","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","CWC","SOXQ","SSG","VGT","BK1191","CHPS","BK4588","EIS","159582","MQQQ","TECY","FWD","CHPY","BK4585","PSI","SOXX","TEKX","VTHR","AGIX","SMHU","SMHX","01477","SOXL","XSD","AIPO","CHAT","SOXS","NBDS","QTOC","BK1574","FTXL","SMH","BK4535","SOXY","USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2673704094","title":"Cantrust (Far East) Limited减持瀚森制药(03692.HK)12.4万股 每股作价约33.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673704094?lang=zh_cn&edition=full","pubTime":"2026-10-05 19:13","pubTimestamp":1791198794,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1574","03692","01477","BK1589","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0531},{"period":"3month","weight":0.002},{"period":"6month","weight":-0.3728},{"period":"1year","weight":-0.3865},{"period":"ytd","weight":-0.3135}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":-0.0421},{"period":"3month","weight":0.0015},{"period":"6month","weight":-0.065},{"period":"1year","weight":-0.095},{"period":"ytd","weight":-0.0554}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.062947},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003589},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.052517},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.073222},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.104041},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}